Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.80 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787588 | 1.00 | TLR9 (0.80) | TLR9HTR6ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL1344338 | 1.00 | TLR9 (0.80) | TLR9HTR6ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL10825832 | 0.89 | TLR9 (1.00) | TLR9HTR6ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL10826201 | 0.89 | TLR9 (1.00) | TLR9HTR6ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL3718697 | 0.85 | TLR9 (0.67) | TLR9HTR6ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL777364 | 0.85 | TLR9 (0.67) | TLR9HTR6ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL11158329 | 0.85 | TLR9 (0.67) | TLR9HTR6ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL1035737 | 0.85 | TLR9 (0.67) | TLR9HTR6ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL10950780 | 0.85 | TLR9 (0.67) | TLR9HTR6ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL777365 | 0.85 | TLR9 (0.67) | TLR9HTR6ALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122051385-A | Additive for improving safety performance of electrolyte, electrolyte and battery | 孝感楚能新能源创新科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-119638541-A | Addition product of alkyl free radical and capture reagent, addition method and application thereof | 深圳湾实验室坪山生物医药研发转化中心 | 2025-03-18 | — | — | CN | claimed |
| CN-116444330-A | Addition product of alkyl free radical and capture reagent, addition method and application thereof | 深圳湾实验室坪山生物医药研发转化中心 | 2023-07-18 | — | — | CN | claimed |
| US-6797745-B1 | Hot melt inks containing styrene or terpene polymers | XEROX CORPORATION | 2004-09-28 | — | — | US | claimed |
| CN-122051385-A | Additive for improving safety performance of electrolyte, electrolyte and battery | 孝感楚能新能源创新科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122051385-A | Additive for improving safety performance of electrolyte, electrolyte and battery | 孝感楚能新能源创新科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2025090901-A1 | ROS-ACTIVATED CO PRODRUGS FOR CANCER TREATMENT | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119638541-A | Addition product of alkyl free radical and capture reagent, addition method and application thereof | 深圳湾实验室坪山生物医药研发转化中心 | 2025-03-18 | — | — | CN | disclosed |
| CN-116444330-A | Addition product of alkyl free radical and capture reagent, addition method and application thereof | 深圳湾实验室坪山生物医药研发转化中心 | 2023-07-18 | — | — | CN | disclosed |
| US-11279686-B2 | Nrf2 activating compounds and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20210078969-A1 | Nrf2 Activating Compounds and Uses Thereof | MIDCAP FINANCIAL TRUST | 2021-03-18 | — | — | US | disclosed |
| EP-3411361-B1 | NRF2 ACTIVATING COMPOUNDS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-6040367-A | EXCELLENT RESISTANCE TO AN IONIZING RADIATION, IN WHICH HETEROCYCLIC COMPOUND CONTAINING OXYMETHYLENE UNITS | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5977206-A | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5948838-A | 0.01 TO 5 PARTS BY WEIGHT OF A COMPOUND CONTAINING OXYMETHYLENE UNIT | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-09-07 | — | — | US | disclosed |
| EP-0794218-A2 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-09-10 | — | — | EP | disclosed |
| EP-0753540-A2 | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-01-15 | — | — | EP | disclosed |
| EP-0127086-B1 | PROCESS FOR THE PURIFICATION OF VITAMIN D3 AND OF VITAMIN D2 | BASF Aktiengesellschaft (DE) | 1986-10-29 | — | — | EP | disclosed |
| US-4529546-A | Purification of vitamin D3 | BASF AKTIENGESELLSCHAFT (DE) | 1985-07-16 | — | — | US | disclosed |
| EP-0127086-A2 | Process for the purification of vitamin D3 and of vitamin D2 | BASF Aktiengesellschaft (DE) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078969-A1 | Nrf2 Activating Compounds and Uses Thereof | NFE2L2, KEAP1, NQO1 | TLR9 819/4885HTR6 3674/4885ALDH1A1 1408/4885 |
| US-11279686-B2 | Nrf2 activating compounds and uses thereof | NFE2L2, KEAP1, NQO1 | TLR9 819/4885HTR6 3674/4885ALDH1A1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.